In pancreatic ductal adenocarcinoma, application of IL6R blocking antibodies through inhibiting IL6 signaling could shift the tumor microenvironment from a chemoresistant state to a chemosensitive state, which was accompanied with reduced STAT3 activation [40]. The gene discussed is IL6R; the disease is pancreatic ductal adenocarcinoma.